Cytoreduction and HIPEC in the treatment of “unconventional” secondary peritoneal carcinomatosis

@inproceedings{Cardi2015CytoreductionAH,
  title={Cytoreduction and HIPEC in the treatment of “unconventional” secondary peritoneal carcinomatosis},
  author={Maurizio Cardi and Paolo Sammartino and Valentina Mingarelli and S Sibio and Fabio Accarpio and Daniele Biacchi and Daniela Musio and Bianca Maria Sollazzo and Angelo di Giorgio},
  booktitle={World journal of surgical oncology},
  year={2015}
}
BACKGROUND Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients and is regarded as the standard of care for pseudomyxoma peritonei from appendiceal cancer and peritoneal mesotheliomas. Improved survival has also been reported in treating PM from ovarian, gastric, and colorectal cancers. However, PM often… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

is there a subset of patients who may benefit from Cardi et al

  • D Baratti, E Pennacchioli, +4 authors sarcomatosis et al. Peritoneal
  • World Journal of Surgical Oncology
  • 2015

Intraperitoneal chemotherapy from peritoneal surface malignancy: experience with 1000 patients

  • EA Levine, JH Stewart, P Shin, GB Russell, BL Loggie, KI. Votanopoulos
  • J Am Coll Surg
  • 2014

Similar Papers

Loading similar papers…